Adarx 制药 ADRX

Ting Feng, Ph.D., has served as a member of our board of directors since October 2025. Dr. Feng has served as Partner at Sirona Capital, a dedicated healthcare venture capital fund, since January 2022. Prior to joining Sirona Capital, Dr. Feng held various investment roles at healthcare venture firms, such as Lilly Asia Ventures (LAV), from December 2018 to January 2022, and SAIF Partners from 2016 to 2018. Dr. Feng currently serves as a member of the board of directors of Synnovation Therapeutics, a precision medicine company, since November 2021. Dr. Feng previously served as a member of the board of members of Shanghai Allist Pharmaceuticals Co., Ltd., a public pharmaceutical company, from November 2019 to March 2022. Dr. Feng also served as a member of the board of directors of ArriVent Biopharma, a public clinical-stage biopharmaceutical company, from June 2021 to January 2022. Dr. Feng received her B.S. in Biotechnology from Wuhan University and her Ph.D. in Immunology from the University of Alabama at Birmingham.

Zhen Li, Ph.D., is one of our founding members and has served as a member of our board of directors since our inception in December 2019 and as our President and Chief Executive Officer since January 2020. Dr. Li also was our Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non-Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering-Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering-Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University.

Ryan Fisk, M.B.A., has served as our Chief Financial Officer and Chief Business Officer since March 2026. Previously, Mr. Fisk served as a Managing Director at Goldman Sachs, an investment bank, from March 2022 to March 2026. From 2016 to March 2022, Mr. Fisk served in various roles at Bank of America Merrill Lynch, an investment bank, including as a Managing Director from 2021 to March 2022 and as a Director and Vice President from 2016 to 2020. Prior to that, Mr. Fisk served in various roles at Credit Suisse, an investment bank, from 2012 to 2016, including as a Vice President and as an Associate. Mr. Fisk received his B.A. in Economics and Political Science from UCLA and his M.B.A. from Columbia Business School.

Judith J. Li, M.B.A., has served as a member of our board of directors since September 2021. Ms. Li has served as Partner at LAV, a biomedical venture capital firm, since November 2013. Ms. Li has served as a member of the board of directors of multiple LAV portfolio companies, including Tmunity Therapeutics Incorporated (acquired by Kite Pharma, Inc., a public biotechnology company, in 2023), a biotechnology company, since January 2016, Scineuro Pharmaceuticals, a private pharmaceutical company, since December 2020, and Fortis Therapeutics, a biotechnology company, since June 2016. Ms. Li previously served as a member of the board of directors at Gritstone Oncology, Inc., a public biotechnology company, from September 2017 to January 2022. Ms. Li has also previously served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, from May 2018 to June 2020, and Nextcure, Inc., a public biopharmaceutical company, from December 2015 to September 2020. Ms. Li received her B.A. in Biology from Harvard University and her M.B.A. from Harvard Business School.

A. Robert MacLeod, Ph.D., has served as our Chief Scientific Officer since January 2023. From September 2021 to December 2022, Dr. MacLeod served as Chief Scientific Officer at Flamingo Therapeutics, Inc., a biotechnology company. Prior to that, Dr. MacLeod served in various roles at Ionis Pharmaceuticals, Inc., a public biotechnology company, from October 2008 to September 2021, including Vice President and Franchise Head of Oncology, Vice President of Oncology and Exploratory Discovery and Executive Director of Discovery Biology. In his prior positions, Dr. MacLeod led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of novel investigational therapeutics and numerous scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University Montreal, Quebec, Canada and his Ph.D. in Cancer Epigenetics from McGill University.

Carl L. Gordon, Ph.D., CFA, has served as a member of our board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc. and Lomond Therapeutics Holdings, Inc., as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly-traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.

Erez Chimovits, M.B.A., has served as a member of our board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University.

Simeon George, M.D., M.B.A., has served as a member of our board of directors since July 2021. Dr. George has served as Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic healthcare investment firm, since September 2020. Dr. George previously served in various roles at S.R. One, Limited (now called GSK Equity Investments, Limited), an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, a biotechnology venture capital firm, from 2007 to September 2020, most recently serving as Chief Executive Officer from January 2018 to September 2020. Dr. George has served as a member of the board of directors of Nkarta, Inc., a public biotechnology company, since February 2020 and previously served on such board of directors from February 2015 to September 2017, CRISPR Therapeutics AG, a public biotechnology company, since March 2015 and Design Therapeutics, Inc., a public biotechnology company, since February 2020. Dr. George previously served as a member of the board of directors of Principia Biopharma Inc. (acquired by Sanofi in 2020), a biopharmaceutical company, from February 2011 to September 2020, Progyny, Inc., a health benefits management company, from May 2012 to October 2019, and Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb in 2022), a public biopharmaceutical company, from May 2017 to August 2022. Dr. George received his B.A. in Neuroscience from Johns Hopkins University, his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.